Nanobubble drink ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04844008 (ClinicalTrials.gov) | October 5, 2021 | 30/3/2021 | Do Nanobubbles Improve Joint Hypoxia? | An Investigation of Whether Orally Delivered Nanobubbles Have a Physiological Effect on Joint Hypoxia? | Rheumatoid Arthritis;Psoriatic Arthritis | Dietary Supplement: Nanobubble drink | University of Oxford | NULL | Recruiting | 18 Years | N/A | All | 20 | N/A | United Kingdom |